- Home
- GNLX vs OCCI Comparison
GNLX vs OCCI Comparison
Compare GNLX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNLX | OCCI |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 120.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | OCCI |
|---|---|---|
| Price | $2.66 | $2.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | 150.4K | ★ 545.3K |
| Earning Date | 01-01-0001 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | ★ 18.10 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $2.79 |
| 52 Week High | $8.54 | $7.17 |
Technical Indicators
Market Signals| Indicator | GNLX | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 26.39 |
| Support Level | $2.54 | N/A |
| Resistance Level | $2.80 | $4.97 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 17.20 | 1.86 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.